103 related articles for article (PubMed ID: 10404842)
1. Effect of enalaprilat on nitric oxide activity in coronary artery disease.
Prasad A; Husain S; Quyyumi AA
Am J Cardiol; 1999 Jul; 84(1):1-6. PubMed ID: 10404842
[TBL] [Abstract][Full Text] [Related]
2. Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition: a potential role of bradykinin.
Prasad A; Husain S; Quyyumi AA
J Am Coll Cardiol; 1999 Mar; 33(3):796-804. PubMed ID: 10080484
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure.
Hornig B; Arakawa N; Haussmann D; Drexler H
Circulation; 1998 Dec 22-29; 98(25):2842-8. PubMed ID: 9860785
[TBL] [Abstract][Full Text] [Related]
4. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart.
Quyyumi AA; Dakak N; Andrews NP; Gilligan DM; Panza JA; Cannon RO
Circulation; 1995 Aug; 92(3):320-6. PubMed ID: 7634444
[TBL] [Abstract][Full Text] [Related]
5. Nitric oxide activity in the atherosclerotic human coronary circulation.
Quyyumi AA; Dakak N; Mulcahy D; Andrews NP; Husain S; Panza JA; Cannon RO
J Am Coll Cardiol; 1997 Feb; 29(2):308-17. PubMed ID: 9014982
[TBL] [Abstract][Full Text] [Related]
6. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilation in patients with chronic heart failure.
Nakamura M; Funakoshi T; Arakawa N; Yoshida H; Makita S; Hiramori K
J Am Coll Cardiol; 1994 Nov; 24(5):1321-7. PubMed ID: 7930256
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibition improves venous endothelial dysfunction in chronic smokers.
Chalon S; Moreno H; Hoffman BB; Blaschke TF
Clin Pharmacol Ther; 1999 Mar; 65(3):295-303. PubMed ID: 10096262
[TBL] [Abstract][Full Text] [Related]
8. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition.
Prasad A; Narayanan S; Husain S; Padder F; Waclawiw M; Epstein N; Quyyumi AA
Circulation; 2000 Jul; 102(1):35-41. PubMed ID: 10880412
[TBL] [Abstract][Full Text] [Related]
9. N-acetylcysteine improves coronary and peripheral vascular function.
Andrews NP; Prasad A; Quyyumi AA
J Am Coll Cardiol; 2001 Jan; 37(1):117-23. PubMed ID: 11153725
[TBL] [Abstract][Full Text] [Related]
10. Contribution of nitric oxide to reactive hyperemia: impact of endothelial dysfunction.
Dakak N; Husain S; Mulcahy D; Andrews NP; Panza JA; Waclawiw M; Schenke W; Quyyumi AA
Hypertension; 1998 Jul; 32(1):9-15. PubMed ID: 9674631
[TBL] [Abstract][Full Text] [Related]
11. Platelet glycoprotein IIb/IIIa receptor blockade improves vascular nitric oxide bioavailability in patients with coronary artery disease.
Heitzer T; Ollmann I; Köke K; Meinertz T; Munzel T
Circulation; 2003 Aug; 108(5):536-41. PubMed ID: 12874186
[TBL] [Abstract][Full Text] [Related]
12. Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects.
Heitzer T; Rudolph V; Schwedhelm E; Karstens M; Sydow K; Ortak M; Tschentscher P; Meinertz T; Böger R; Baldus S
Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1648-52. PubMed ID: 16675725
[TBL] [Abstract][Full Text] [Related]
13. AT1-receptor antagonism improves endothelial function in coronary artery disease by a bradykinin/B2-receptor-dependent mechanism.
Hornig B; Kohler C; Schlink D; Tatge H; Drexler H
Hypertension; 2003 May; 41(5):1092-5. PubMed ID: 12654707
[TBL] [Abstract][Full Text] [Related]
14. Intracoronary enalaprilat improves metabolic coronary vasodilation in patients with idiopathic dilated cardiomyopathy.
Mohri M; Tagawa H; Egashira K; Takeshita A
J Cardiovasc Pharmacol; 2000 Feb; 35(2):249-55. PubMed ID: 10672857
[TBL] [Abstract][Full Text] [Related]
15. Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability.
Prasad A; Andrews NP; Padder FA; Husain M; Quyyumi AA
J Am Coll Cardiol; 1999 Aug; 34(2):507-14. PubMed ID: 10440166
[TBL] [Abstract][Full Text] [Related]
16. Endothelium-dependent vasodilation is augmented by angiotensin converting enzyme inhibitors in healthy volunteers.
Nakamura M; Funakoshi T; Yoshida H; Arakawa N; Suzuki T; Hiramori K
J Cardiovasc Pharmacol; 1992 Dec; 20(6):949-54. PubMed ID: 1282598
[TBL] [Abstract][Full Text] [Related]
17. Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme.
Kuga T; Mohri M; Egashira K; Hirakawa Y; Tagawa T; Shimokawa H; Takeshita A
J Am Coll Cardiol; 1997 Jul; 30(1):108-12. PubMed ID: 9207629
[TBL] [Abstract][Full Text] [Related]
18. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis.
Quyyumi AA; Dakak N; Andrews NP; Husain S; Arora S; Gilligan DM; Panza JA; Cannon RO
J Clin Invest; 1995 Apr; 95(4):1747-55. PubMed ID: 7706483
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease.
Fichtlscherer S; Dimmeler S; Breuer S; Busse R; Zeiher AM; Fleming I
Circulation; 2004 Jan; 109(2):178-83. PubMed ID: 14662709
[TBL] [Abstract][Full Text] [Related]
20. The role of nitric oxide in bradykinin-induced dilation of coronary resistance vessels in patients with hypercholesterolemia.
Kato M; Shiode N; Teragawa H; Hirao H; Yamada T; Yamagata T; Matsuura H; Kajiyama G
Intern Med; 1999 May; 38(5):394-400. PubMed ID: 10397075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
